Merck Makes a Bold Move That Could Transform Its Business
Now, Merck (NYSE: MRK) is making a similar move, recently announcing plans to acquire Prometheus Biosciences (NASDAQ: RXDX). Prometheus Biosciences is an unprofitable business that incurred losses totaling $141.8 million last year on revenue of only $6.8 million.